HEMORRHAGE RISK AFTER ULTRASOUND-GUIDED ABDOMINAL PARACENTESIS EXTREMELY LOW WITHOUT THE USE OF PROPHYLACTIC BLOOD PRODUCT TRANSFUSIONS
AUTHORS

Qasim Rahman, M.D.¹
Michael Rowley, M.D.²
Lauren Cole, M.D.²
Anil Seetharam, M.D.¹²
Kevin Hirsch, M.D.¹²

¹University of Arizona College of Medicine-Phoenix
²Banner University Medical Center-Phoenix

THE AUTHORS OF THIS STUDY HAVE NO DISCLOSURES
TARGET AUDIENCE

• General Radiologists
• Interventional Radiologists
• Gastroenterologists/Hepatologists
ABDOMINAL PARACENTESIS

- Abdominal paracentesis (AP) is the most commonly performed procedure in patients with cirrhosis and is done for both diagnostic and therapeutic purposes.
- AP was the 30th most commonly performed inpatient procedure overall in the United States with 174,825 procedures in 2014 alone.
The most common, major complication of AP is hemorrhage.

No study has shown an association between low platelet count or increased International Normalized Ratio (INR) and bleeding risk.

Many practitioners have concerns about the risk of major hemorrhage in settings of abnormal lab values.

A key factor contributing to the variation in clinical practice and concern is the discrepant state of widely utilized guidelines (i.e. American Association for the Study of Liver Disease (AASLD), Society of Interventional Radiology (SIR))
OBJECTIVE

• Determine the rate of hemorrhage after ultrasound-guided abdominal paracentesis (USAP) procedures performed by experienced radiologists without the use of prophylactic blood product transfusions.
METHODS

• Protocol approved by IRB at our institution
• Retrospective study
• Cohort included both inpatient and outpatient procedures performed over 2-year period
• All USAP performed by experienced radiologists
  • 5F multi-side-hole catheter or 16-gauge angiocath used
  • Patients ≥ 5 L of ascites removed routinely received 12.5 grams of albumin for every liter removed.
• Prophylactic transfusion policy for USAP similar to AASLD (i.e. no transfusion blood products given due to any abnormality with INR or platelet count)
METHODS

• Data Collected:
  • Age at time of procedure
  • Admission/discharge dates
  • Volume of ascites fluid removed (inpatients)
  • Hemoglobin, platelet count, International Normalized Ratio (INR), creatinine, bilirubin and ascites fluid studies
  • Need for dialysis
  • Patients who received any blood products, who were admitted, re-admitted, presented to the ED, or underwent an angiogram were individually reviewed.

• FFP and Cost-Savings Analysis:
  • Patients with INR > 2.0 identified as those who would have received FFP by current guidelines.
  • The cost of FFP was estimated at $400/unit and platelet at $1000/transfusion
RESULTS

- Mean age 56.6 years
- 3116 USAPs performed over 2 years for both inpatient (n=757) and outpatient (n=2359)
- Baseline parameters and demographics shown to the right (and next slide)

### Inpatient and Outpatient Baseline Laboratory Parameters

<table>
<thead>
<tr>
<th></th>
<th>All</th>
<th>No Bleeding Event</th>
<th>Bleeding Event</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hemoglobin (g/dL)</strong></td>
<td>9.9 (2.0)</td>
<td>9.9 (2.0)</td>
<td>9.8 (1.5)</td>
<td>0.9068</td>
</tr>
<tr>
<td><strong>Platelet Count (10^9/μL)</strong></td>
<td>121 (82)</td>
<td>121 (82)</td>
<td>138 (63)</td>
<td>0.6234</td>
</tr>
<tr>
<td><strong>Platelet Count (10^9/μL)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 50</td>
<td>368 (12)</td>
<td>368 (12)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>≥ 50</td>
<td>2749 (88)</td>
<td>2743 (88)</td>
<td>6 (100)</td>
<td></td>
</tr>
<tr>
<td><strong>INR</strong></td>
<td>1.6 (0.6)</td>
<td>1.6 (0.6)</td>
<td>2.0 (0.8)</td>
<td>0.1132</td>
</tr>
<tr>
<td><strong>INR</strong></td>
<td>0.1992</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤2</td>
<td>437 (14%)</td>
<td>435 (14%)</td>
<td>2 (33%)</td>
<td></td>
</tr>
<tr>
<td>&gt;2</td>
<td>2679 (86%)</td>
<td>2675 (86%)</td>
<td>4 (67%)</td>
<td></td>
</tr>
<tr>
<td><strong>Creatine (mg/dL)</strong></td>
<td>2.0 (2.4)</td>
<td>2.0 (2.4)</td>
<td>2.3 (1.7)</td>
<td>0.8155</td>
</tr>
</tbody>
</table>
On univariate analysis, no risk factors were identified that predicted post-USAP bleeding.

<table>
<thead>
<tr>
<th></th>
<th>All</th>
<th>No Bleeding Event</th>
<th>Bleeding Event</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n= 3116</td>
<td>n=3110</td>
<td>n=6</td>
</tr>
<tr>
<td>Dialysis?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>707 (23%)</td>
<td>705 (23%)</td>
<td>2 (33%)</td>
</tr>
<tr>
<td>No</td>
<td>2409 (77%)</td>
<td>2405 (77%)</td>
<td>4 (67%)</td>
</tr>
<tr>
<td>Bilirubin (mg/dL)</td>
<td>3.5 (5.8)</td>
<td>3.5 (5.8)</td>
<td>7.8 (10.4)</td>
</tr>
<tr>
<td>MELD²</td>
<td>18 (8)</td>
<td>18 (8)</td>
<td>24 (11)</td>
</tr>
</tbody>
</table>

1. INR = International Normalized Ratio  2. MELD = Model End Stage Liver Disease Score

***Data listed as mean+/−standard deviation or number with percentage
• 6 of 3116 (0.19%) patients experienced post-USAP bleeding requiring pRBC (1 inpatient, 5 outpatient)
  • 1 patient required urgent angiogram and embolization of a bleeding abdominal wall vessel.
• No deaths due to USAP-related complications
• Baseline parameters for those 6 patients shown to the right

**RESULTS**

### Characteristics of Patients with Bleeding Event

<table>
<thead>
<tr>
<th></th>
<th>Hgb(^1) (g/dL)</th>
<th>Platelets (x10^3/μL)</th>
<th>INR(^2)</th>
<th>Creatinine (mg/dL)</th>
<th>Dialysis</th>
<th>Bilirubin (mg/dL)</th>
<th>MELD(^3)</th>
<th>RBCs(^4)</th>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>7.7</td>
<td>187</td>
<td>3.6</td>
<td>3.04</td>
<td>Yes</td>
<td>27.9</td>
<td>40</td>
<td>1</td>
<td>No</td>
</tr>
<tr>
<td>2</td>
<td>9.4</td>
<td>82</td>
<td>2.2</td>
<td>1.7</td>
<td>No</td>
<td>10</td>
<td>29</td>
<td>1</td>
<td>No</td>
</tr>
<tr>
<td>3</td>
<td>11.8</td>
<td>234</td>
<td>1.4</td>
<td>1.7</td>
<td>No</td>
<td>4.4</td>
<td>21</td>
<td>5</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>10</td>
<td>104</td>
<td>1.7</td>
<td>5.28</td>
<td>Yes</td>
<td>1.8</td>
<td>28</td>
<td>1</td>
<td>No</td>
</tr>
<tr>
<td>5</td>
<td>8.9</td>
<td>76</td>
<td>1.9</td>
<td>0.84</td>
<td>No</td>
<td>1.6</td>
<td>15</td>
<td>2</td>
<td>No</td>
</tr>
<tr>
<td>6</td>
<td>11.1</td>
<td>143</td>
<td>1.3</td>
<td>1</td>
<td>No</td>
<td>1.1</td>
<td>10</td>
<td>2</td>
<td>No</td>
</tr>
</tbody>
</table>

Hgb = Hemoglobin  INR = International Normalized Ratio  MELD = Model End Stage Liver Disease Score  PRBCs = Packed Red Blood Cells
RESULTS-COST ANALYSIS

• FFP savings
  • 247 inpatients (33%) and 188 outpatients (8%) had INRs >2.0 and would have required FFP transfusion based on current guidelines
  • Would require 1-5 units of FFP. Therefore, savings of $450,000 over a 2-year period.

• Platelet savings
  • 131 (17%) inpatients and 235 (8%) outpatients with a platelet count under 50 x 10^3 /µL would have required transfusion per guidelines.
  • Would require single donor platelet transfusions. Therefore, savings of $366,000 over study period.
DISCUSSION & SUMMARY

• USAP is a very safe procedure with extremely low rates of bleeding without the use of prophylactic blood product transfusions for correction of coagulation abnormalities.

• No variables were found to be predictive of hemorrhagic complications including MELD, INR, platelet count or degree of renal dysfunction.

• A no-prophylactic transfusion policy leads to avoidance of unnecessary risks to the patient and significant cost and resource savings.
• Thank you for your attention!
REFERENCES

• https://www.ahrq.gov/research/data/hcup/index.html
• Schuerman S. Care of patients receiving long-term anticoagulant therapy 2003; 349: 675-683.